Protalix BioTherapeutics (PLX) Current Taxes (2023 - 2026)

Protalix BioTherapeutics' Current Taxes history runs 4 years deep, the most recent figure standing at $3.2 million for Q1 2026.

• On a quarterly basis, Current Taxes fell 7.85% year-over-year to $3.2 million in Q1 2026; TTM through Mar 2026 was $3.2 million, a 7.85% decrease from a year earlier, with the FY2025 full-year figure at $2.9 million, down 15.13% from the prior year.
• Current Taxes advanced to $3.2 million in Q1 2026 per PLX's latest filing, from $2.9 million in the prior quarter.
• Across five years, Current Taxes topped out at $3.7 million in Q2 2025 and bottomed at $2.4 million in Q3 2025.
• The 4-year median for Current Taxes is $3.2 million (2026), against an average of $3.2 million.
• Across the five-year window, Current Taxes advanced 20.86% in 2024 and retreated 15.13% in 2025, its largest moves.
• Year by year, Current Taxes stood at $2.9 million in 2023, then grew by 20.86% to $3.5 million in 2024, then decreased by 15.13% to $2.9 million in 2025, then climbed by 8.58% to $3.2 million in 2026.
• Per Business Quant, the three latest PLX Current Taxes figures stand at $3.2 million (Q1 2026), $2.9 million (Q4 2025), and $2.4 million (Q3 2025).